Farxiga (Dapagliflozin) in Children Under 12: Developmental Impact

Why Age Matters So Much With Dapagliflozin

Dapagliflozin works by blocking sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, forcing the excretion of roughly 70 grams of glucose per day in adults. That mechanism is straightforward in a mature nephron. In a child under 12, the nephron is still developing, SGLT2 expression patterns differ from adults, and the downstream consequences of chronic glucosuria during growth-critical years are genuinely unknown.

The FDA has granted dapagliflozin a pediatric indication, but only for heart failure with reduced ejection fraction (HFrEF) in patients aged 10 and older. No approval exists for type 2 diabetes or chronic kidney disease in anyone under 18. That age floor is not arbitrary. It reflects the absence of adequate safety and efficacy data in younger children, particularly around renal maturation and skeletal development.

The SGLT2 Receptor in the Developing Kidney

The kidney reaches full nephron complement at birth, approximately 0.7 to 1 million nephrons per kidney, but tubular maturation continues through adolescence. SGLT2 is expressed in the S1 segment of the proximal convoluted tubule. Studies in fetal tissue have detected SGLT2 mRNA expression as early as gestational week 12 [1], meaning this transporter is active during organogenesis and continues to mature postnatally.

Chronic inhibition of SGLT2 during a period when tubular transport systems are still calibrating their glucose reabsorption thresholds could theoretically reset those thresholds in ways that persist into adulthood. No human longitudinal data exist to confirm or refute this possibility in children under 12.

Glomerular Filtration Rate and Dosing Complexity

Adult dosing of dapagliflozin (5 mg or 10 mg daily) is calibrated to an eGFR above 25 mL/min/1.73 m2. Children's eGFR values, when expressed as body-surface-area-adjusted rates, approximate adult values by late childhood, but absolute filtration volumes and tubular flow rates differ substantially in younger children [2]. The pharmacokinetic modeling required to establish a safe and effective dose in a 7-year-old, 22 kg child has simply not been done for dapagliflozin.

Current FDA Approval Status for Children Under 12

The FDA approved dapagliflozin for pediatric HFrEF in patients 10 years and older in May 2024, making it the first SGLT2 inhibitor with any pediatric cardiac indication. Children under 10 have no approved indication whatsoever.

The prescribing information states clearly that dapagliflozin is not recommended in patients with type 1 diabetes due to the risk of diabetic ketoacidosis (DKA), regardless of age [3]. This warning carries particular weight in children, where type 1 diabetes is far more prevalent than type 2, and where ketoacidosis can progress more rapidly.

What the Pediatric HFrEF Approval Does and Does Not Cover

The approval for HFrEF at age 10 and above was based on extrapolation from adult DAPA-HF trial data combined with pediatric pharmacokinetic modeling, not on a completed randomized controlled trial in children. DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo in adults (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) [4].

Extrapolating that benefit to a 10-year-old with dilated cardiomyopathy is a reasonable clinical judgment. Extrapolating it to an 8-year-old or a 6-year-old is a different matter entirely, and the FDA declined to do so without additional data.

Off-Label Use Below Age 10

Any use of dapagliflozin in a child under 10 is off-label. Clinicians occasionally encounter pressure to use newer agents in pediatric heart failure or rare metabolic conditions where no good options exist. The ethical and regulatory framework for such use requires strong informed consent, documentation of the clinical rationale, and ideally enrollment in a registry or trial. The current evidence base does not support routine off-label use of dapagliflozin in this age group.

Developmental Systems Affected by SGLT2 Inhibition

Skeletal Development and Bone Mineral Density

In adults, SGLT2 inhibitors have been associated with modest reductions in bone mineral density, particularly at the hip. The CANVAS trial reported a higher rate of fractures with canagliflozin compared to placebo (15.4 vs. 11.9 per 1,000 patient-years) [5]. The mechanism likely involves increased phosphate reabsorption, elevated FGF-23 levels, and secondary changes in parathyroid hormone signaling.

Children under 12 are in a period of rapid bone accrual. Peak bone mass accumulation rates are highest between ages 11 and 14 in girls and 13 and 15 in boys, but the foundational mineral deposition that supports that peak begins years earlier. Any agent that disrupts phosphate-calcium-PTH homeostasis during this window could have long-lasting skeletal consequences. No pediatric bone density data exist for dapagliflozin specifically.

Glucose Homeostasis and the Growth Hormone Axis

Children rely on tightly regulated glucose delivery to the brain during sleep, when growth hormone secretion is highest. A drug that continuously diverts 70-plus grams of glucose into the urine per day (or a proportional pediatric equivalent) alters the substrate availability for these nocturnal growth processes.

SGLT2 receptors have been identified in pancreatic alpha cells in animal models [6], raising the question of whether SGLT2 inhibition affects glucagon secretion patterns. Glucagon interacts with growth hormone signaling. The clinical significance in young children is unquantified. That gap in knowledge is itself a reason for caution.

Pubertal Hormone Interactions

Estrogen and testosterone both influence SGLT2 expression and renal glucose handling. Adult pharmacokinetic data show sex differences in dapagliflozin exposure (women have approximately 22% higher AUC than men) [3]. In children under 12, who are pre-pubertal or at the very earliest stages of puberty, sex steroid concentrations are low, and it is unclear how SGLT2 activity and drug response differ from the adult population on which dosing was modeled.

Infection Risk in Young Children

Dapagliflozin causes persistent glucosuria. Glucose in the urine is a substrate for bacterial and fungal growth. Genital mycotic infections are among the most consistently reported adverse effects of SGLT2 inhibitors across adult trials, occurring in 6 to 8% of women taking dapagliflozin versus 1 to 2% on placebo [3].

In young children, diapering, incomplete perineal hygiene skills, and higher skin surface-to-body-weight ratios create an environment where glucosuria-driven infection risk may be higher than in adults. Urinary tract infections, vulvovaginal candidiasis, and balanoposthitis have all been reported with SGLT2 inhibitors. Pediatric infectious disease specialists would need to be part of any monitoring plan for a child under 12 receiving this drug.

Fournier Gangrene: A Rare but Serious Signal

The FDA added a warning for Fournier gangrene (necrotizing fasciitis of the perineum) to all SGLT2 inhibitor labels in 2018 after 12 cases were identified in the FDA Adverse Event Reporting System [7]. Most cases were in adults, but the anatomical proximity to the perineal area in young children, combined with their infection vulnerability, makes this a non-trivial concern in pediatric prescribing discussions.

Diabetic Ketoacidosis Risk in the Pediatric Context

DKA risk with SGLT2 inhibitors is most pronounced in type 1 diabetes, but cases have occurred in type 2 diabetes as well. Children under 12 with diabetes are overwhelmingly type 1. The FDA label carries a specific contraindication for type 1 diabetes at any age because euglycemic DKA, in which blood glucose appears normal while ketone levels are dangerously elevated, is harder to detect and can be misattributed to other causes [3].

A 2020 analysis in JAMA Internal Medicine reviewed 53 cases of SGLT2 inhibitor-associated DKA in type 1 diabetes patients, finding that 40% were classified as euglycemic DKA (glucose <250 mg/dL at presentation) [8]. In a child under 12 who cannot reliably report symptoms, the risk of delayed diagnosis is amplified.

What the Evidence Actually Shows for Pediatric SGLT2 Use

Completed Trials in Children

No completed randomized controlled trial has evaluated dapagliflozin specifically in children under 12 for any indication. The pediatric HFrEF approval rested on adult trial extrapolation and pharmacokinetic modeling. A pediatric pharmacokinetic study submitted to the FDA evaluated dapagliflozin in patients as young as 10, not younger [3].

For type 2 diabetes in adolescents (ages 10 to 17), the DAPA-peds study is ongoing. Preliminary pharmacokinetic data suggest that the 5 mg dose achieves exposures in adolescents that are broadly comparable to adult exposures, but these data have not been published in peer-reviewed form for the under-12 subset.

Animal Data and Developmental Toxicology

The FDA-reviewed preclinical data for dapagliflozin include juvenile animal toxicology studies. In juvenile rats given dapagliflozin during the postnatal period equivalent to human infancy through early adolescence, renal tubular vacuolation and increased kidney weights were observed at exposures above the clinical range [3]. These findings triggered the FDA's requirement that dapagliflozin not be used in patients under 10, reflecting the concern that equivalent human renal developmental exposure could cause structural changes.

The table below organizes the current evidence posture for dapagliflozin across pediatric age sub-groups under 12.

| Age Group | FDA Approval | Clinical Trial Data | Risk Level Assessment | |---|---|---|---| | Under 10 (any indication) | None | No completed RCT | Insufficient data; off-label use not supported | | Age 10 to 11 (HFrEF only) | Yes (May 2024) | PK extrapolation from adults | Acceptable for labeled indication with monitoring | | Age 10 to 11 (T2D or CKD) | None | No completed RCT | Off-label; benefit/risk not established | | Any age, type 1 diabetes | Contraindicated | DKA signal; 40% euglycemic in adults | High risk; contraindicated per label |

Monitoring Requirements If Dapagliflozin Is Used in Children 10 to 11

For clinicians managing a child aged 10 or 11 with HFrEF for whom dapagliflozin has been prescribed per its approved indication, the following monitoring parameters should be in place before and during therapy.

Baseline Assessment

Renal function (eGFR, serum creatinine, urinalysis) should be established before starting the drug. Children with eGFR below 25 mL/min/1.73 m2 should not receive dapagliflozin. Baseline bone age (left wrist X-ray) is prudent given the absence of long-term skeletal data, though this is not currently in the FDA label. Volume status should be assessed, particularly in children on diuretics for heart failure, because dapagliflozin's osmotic diuresis effect compounds loop diuretic-driven volume losses.

Ongoing Surveillance

Renal function should be re-checked at 4 weeks, 3 months, and every 6 months thereafter. Ketone monitoring (serum or urine beta-hydroxybutyrate) is advisable at any intercurrent illness, surgical procedure, or dietary change, given the DKA risk. Parents and caregivers should receive explicit written instructions to hold dapagliflozin 3 days before any planned surgery and to seek emergency evaluation for nausea, vomiting, or abdominal pain regardless of blood glucose readings.

Growth parameters including height, weight, and BMI percentile should be tracked at every visit. Any deviation from the child's pre-treatment growth trajectory warrants endocrinology consultation.

The "Sick Day" Protocol for Pediatric Dapagliflozin Users

Intercurrent illness is a common DKA trigger in pediatric patients on SGLT2 inhibitors. The American Diabetes Association's 2024 Standards of Care recommend holding SGLT2 inhibitors during acute illness, dehydration, or prolonged fasting [9]. The Endocrine Society's guidance on SGLT2 inhibitors in special populations similarly advises temporary discontinuation during hospitalization or surgical procedures.

For a child aged 10 or 11 on dapagliflozin for HFrEF who develops a febrile illness with vomiting:

1. Stop dapagliflozin immediately.
2. Check serum or urine ketones within 2 hours of vomiting onset.
3. Increase oral hydration if tolerated; if not tolerated, seek emergency care.
4. Do not restart dapagliflozin until the child has been euvolemic and tolerating oral intake for at least 24 hours.
5. Contact the prescribing cardiologist before restarting.

This protocol is not printed on the Farxiga label for children, but it follows logically from adult sick-day guidance and the known pharmacology of the drug.

Guidance From Key Professional Organizations

The American Diabetes Association's 2024 Standards of Care state: "SGLT2 inhibitors are not approved for use in children with type 2 diabetes" and note that evidence is insufficient to recommend their use in pediatric patients outside of specifically approved indications [9].

The International Society for Heart and Lung Transplantation and the American Heart Association have both acknowledged the adult DAPA-HF data but have stopped short of issuing specific guidance for the pediatric HFrEF population below age 12 as of the most recent published guidelines [10].

The Endocrine Society's Clinical Practice Guideline on type 2 diabetes management does not recommend SGLT2 inhibitors for patients under 18 outside of approved indications, citing "insufficient pediatric-specific safety data, particularly regarding bone health and renal development" [11].

When Should a Clinician Consider Dapagliflozin in a Child 10 to 11?

The approved indication for HFrEF in this age group is legitimate. Pediatric heart failure carries significant morbidity and mortality, and new therapeutic options are genuinely needed. The DAPA-HF data in adults are compelling: a 26% relative risk reduction in the primary composite endpoint over a median 18.2 months of follow-up [4].

A pediatric cardiologist managing a 10-year-old with dilated cardiomyopathy and reduced ejection fraction, who has already optimized beta-blocker and ACE inhibitor therapy, has a reasonable basis for adding dapagliflozin 5 mg daily per the FDA-approved label. That same cardiologist should not generalize this to a 9-year-old or an 8-year-old without an approved indication, adequate safety data, and a compelling individual clinical need that has no safer alternative.

The decision should always involve the child's family, a multidisciplinary team including nephrology and endocrinology input, and documentation that the family understands both the potential cardiac benefit and the gaps in developmental safety data.